Tesamorelin

1. Product Overview

Tesamorelin (code TH9507) is a stabilized 44-amino-acid synthetic analog of human endogenous Growth Hormone-Releasing Hormone (GHRH). Modified with trans-3-hexenoic acid at the N-terminus, it gains strong resistance to DPP-IV enzymatic degradation and longer in-vivo half-life compared to native GHRH.

Our Tesamorelin is synthesized and purified under strict biotech standards to form stable white lyophilized powder. It selectively binds pituitary GHRH receptors to trigger pulsatile endogenous growth hormone secretion, instead of exogenous GH supplementation, making it a gold-standard research tool for hypothalamic-pituitary endocrine axis, visceral adipose regulation and metabolic disorder mechanism studies. Every batch undergoes rigorous HPLC purity detection and mass spectrometry structural identification; complete Certificate of Analysis, chromatograms and MS spectra are provided for all orders to guarantee repeatable lab experimental results.

Basic chemical info:

CAS: 218949-48-5 (free base)
Molecular Weight: 5135.9 g/mol

2. Available Specifications

SKU Options:

TSM5: 5mg per vial, 10 vials per kit
TSM10: 10mg per vial, 10 vials per kit
TSM20: 20mg per vial, 10 vials per kit

Custom bulk synthesis and customized single-vial dosage can be arranged upon customer inquiry for large-scale animal trials and formulation research.

3. Core Preclinical Research Applications

Visceral Adipose Tissue & Lipodystrophy Research

Exhibits targeted lipolysis effect on visceral fat with minimal influence on subcutaneous fat; widely applied in HIV-associated lipodystrophy, metabolic syndrome and obesity rodent models to study abdominal fat reduction and lipid profile improvementexcaliburp….
GH/IGF-1 Endocrine Axis Mechanism Study

Stimulates physiological pulsatile GH release to upregulate hepatic IGF-1 expression; ideal reagent for exploring growth hormone secretion, muscle anabolism and lean mass regulation pathways.
Non-Alcoholic Fatty Liver Disease (NAFLD) Research

Reduces intrahepatic lipid accumulation and improves insulin sensitivity for liver fat metabolism exploratory experiments.
Aging & Cognitive Function Research

Regulates age-related endocrine decline, alleviates frailty and improves spatial memory in aging animal models for anti-aging neuroscience research.
Compound Endocrine Peptide Stack Research

Commonly combined with Ipamorelin, CJC-1295 and Sermorelin to build multi-target GH-axis synergistic research formulas.

4. Strict Quality Control Standards

HPLC purity ≥99%
Mass spectrometry (MS) full structural identity verification
Endotoxin level controlled below 0.1 EU/mg
Independent batch COA, HPLC chromatogram and MS spectrum attached
Comprehensive detection of residual solvents, heavy metals, oxidation impurities and moisture

5. Storage & Shipping Guidance

Lyophilized powder storage: Seal tightly, store at -20°C, avoid light, high temperature and humid environment; stable for 2–3 years under proper sealed preservation.
After reconstitution: Store at 2–8°C, avoid repeated freeze-thaw cycles to prevent peptide degradation and activity loss; finish use within 30 days after dilution.
Global delivery: Low-temperature insulated cold-chain packaging protects peptide biological activity during cross-border transportation.
Technical service: Our professional R&D team provides reconstitution protocols, storage specifications and experimental scheme consultation within 24 working hours.

6. Important Disclaimer

This lyophilized Tesamorelin peptide powder is for laboratory research use only. It is not approved for human injection, oral administration, clinical treatment or veterinary medication. The research-grade product is different from pharmaceutical Egrifta® and cannot be used for clinical therapy.